PURPOSE: To determine the overall survival for patients with metastatic pancreatic cancer treated with lapatinib and gemcitabine. MATERIALS AND METHODS: Patients with metastatic pancreatic cancer received lapatinib, 1,500 mg/d, and Gemcitabine, 1 g/m(2)/wk for 3 weeks followed by 1 week off, until disease progression. This multicenter phase II study was planned to enter 125 patients to evaluate whether the treatment regimen could achieve a 1-year survival of 30% and a median survival of 7 months. An additional subset of 20 patients were to receive 2 months of single agent lapatinib followed by lapatinib and gemcitabine. RESULTS: At a planned 6 month analysis, the Brown University Oncology Group Data Safety Monitoring Board terminated accrual after 29 patients because of futility analysis. The median survival was 4 months (95% confidence interval, 3.0-5.0 months). Three of the 29 (10%) patients had a partial response. The 4 patients who received single agent lapatinib all progressed at 1 month. CONCLUSION: Lapatinib is not effective in pancreatic cancer. Evaluation of HER2 inhibitors in pancreatic cancer is not warranted.
PURPOSE: To determine the overall survival for patients with metastatic pancreatic cancer treated with lapatinib and gemcitabine. MATERIALS AND METHODS:Patients with metastatic pancreatic cancer received lapatinib, 1,500 mg/d, and Gemcitabine, 1 g/m(2)/wk for 3 weeks followed by 1 week off, until disease progression. This multicenter phase II study was planned to enter 125 patients to evaluate whether the treatment regimen could achieve a 1-year survival of 30% and a median survival of 7 months. An additional subset of 20 patients were to receive 2 months of single agent lapatinib followed by lapatinib and gemcitabine. RESULTS: At a planned 6 month analysis, the Brown University Oncology Group Data Safety Monitoring Board terminated accrual after 29 patients because of futility analysis. The median survival was 4 months (95% confidence interval, 3.0-5.0 months). Three of the 29 (10%) patients had a partial response. The 4 patients who received single agent lapatinib all progressed at 1 month. CONCLUSION:Lapatinib is not effective in pancreatic cancer. Evaluation of HER2 inhibitors in pancreatic cancer is not warranted.
Authors: Katrin M Sjoquist; Venessa T Chin; Lorraine A Chantrill; Chelsie O'Connor; Chris Hemmings; David K Chang; Angela Chou; Marina Pajic; Amber L Johns; Adnan M Nagrial; Andrew V Biankin; Desmond Yip Journal: World J Gastroenterol Date: 2014-06-28 Impact factor: 5.742
Authors: N Ioannou; A G Dalgleish; A M Seddon; D Mackintosh; U Guertler; F Solca; H Modjtahedi Journal: Br J Cancer Date: 2011-10-04 Impact factor: 7.640
Authors: R van der Noll; W M Smit; A N M Wymenga; D S Boss; M Grob; A D R Huitema; H Rosing; M M Tibben; M Keessen; H Rehorst; J H Beijnen; J H M Schellens Journal: Invest New Drugs Date: 2015-09-11 Impact factor: 3.850
Authors: Linnéa Malgerud; Johan Lindberg; Valtteri Wirta; Maria Gustafsson-Liljefors; Masoud Karimi; Carlos Fernández Moro; Katrin Stecker; Alexander Picker; Carolin Huelsewig; Martin Stein; Regina Bohnert; Marco Del Chiaro; Stephan L Haas; Rainer L Heuchel; Johan Permert; Markus J Maeurer; Stephan Brock; Caroline S Verbeke; Lars Engstrand; David B Jackson; Henrik Grönberg; Johannes Matthias Löhr Journal: Mol Oncol Date: 2017-08-08 Impact factor: 6.603